Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02192398 · ClinicalTrials.gov registry record · NA
Effect of Guanfacine on the Reversal of Opioid-induced Hyperalgesia (OIH)
A NA study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- NA
- Development phase
- 8
- Enrollment target
NCT02192398: Clinical Trial NA study, sponsored by Massachusetts General Hospital.
NCT02192398 is a NA study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02192398, a NA study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- NA
- Development phase
- 8 participants
- Enrollment target
Study Summary
Combination of guanfacine with opioid medication as a standard treatment for chronic pain.
Interventions
- DRUG Placebo
- DRUG Guanfacine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2014-09 |
| Est. Completion | 2022-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02192398
The ClinicalTrials.gov registry entry for NCT02192398 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02192398 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02192398 about?
NCT02192398 is a clinical study titled "Effect of Guanfacine on the Reversal of Opioid-induced Hyperalgesia (OIH)". Combination of guanfacine with opioid medication as a standard treatment for chronic pain.
What is the current status of trial NCT02192398?
This trial is currently terminated. It is a NA study. The enrollment target is 8 participants. The study started on 2014-09. Estimated completion is 2022-10.
What interventions are being tested in trial NCT02192398?
The interventions under investigation include: Placebo (DRUG), Guanfacine (DRUG).
Who is sponsoring clinical trial NCT02192398?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.